Latest from Weill Cornell Sandra & Edward Meyer Cancer Center

Prestigious award supports promising new direction in brain cancer research at Weill Cornell Medicine and NewYork-Presbyterian.
Dr Olivier Elemento, a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.
Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence grant from the National Cancer Institute to improve the detection, diagnosis and treatment of prostate cancer, a disease that affects one in six men.
Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).
Gail J. Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019) in patients with acute lymphoblastic leukemia.
Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses evolving paradigms in treatment of patients with acute myeloid leukemia (AML).
David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.
 
Publication Bottom Border
Border Publication